Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 4Pain, Postoperative 2Vesico-Ureteral Reflux 1Uterine Neoplasms 1Ureteral Neoplasms 1Peritoneal Cancer 1Pancreatic Neoplasms 1Pain 1Ovarian Neoplasms 1Neuralgia 1Nephrolithiasis 1Neoplasms 1Malignant Neoplasms of Female Genital Organs 1Lung Neoplasms 1Leiomyoma 1Kidney Neoplasms 1Endometrial Neoplasms 1Endometrial Hyperplasia 1Digestive System Diseases 1Breast Cancer Female 1Abdominal Cancer 1

Interventions

Bupivacaine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Peritoneal Cancer × Bupivacaine × Clear all
NCT03359811 2022-02-18

Four Quadrants Transverse Abdominus Plane (4Q-TAP) Block With Plain and Liposomal Bupivacaine vs. Thoracic Epidermal Analgesia (TEA) in Patients Undergoing Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) on an Enhanced Recovery Pathway

M.D. Anderson Cancer Center

Phase 3 Completed
75 enrolled 21 charts

Peritoneal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡